Back

Comparative effectiveness of lipid-lowering regimens for achieving ESC LDL-cholesterol targets in acute coronary syndrome: a real-world cohort analysis

31 August 2026 (09:15 - 10:00)
Organised by: Logo
Congress Presentation Part of: Implementing novel lipid‑lowering therapies Lipid-Lowering Agents ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Miss Asimina Romiou

Sismanoglion Hospital, Marousi (Greece)

5 More presentations in this session

Presentation thumbnail
The nocebo effect in statin therapy: clinical implications for adherence and cardiovascular outcomes
Doctor M. Sargsyan (Yerevan, AM)
Abstract
Presentation thumbnail
Impact of evolocumab on coronary plaque stratified by very high-risk ASCVD status: a YELLOW III sub study
Doctor P. C Revaiah (New York, US)
Abstract
Presentation thumbnail
Variability in lipoprotein(a) measurements in ODYSSEY OUTCOMES: is one-and-done testing sufficient?
Professor P. Steg (Paris, FR)
Abstract
Presentation thumbnail
Nationwide implementation of PCSK9--targeted therapies after myocardial infarction and ischemic stroke: structural barriers and disparities in a universal healthcare system
Assistant Professor P. Sedova (Brno, CZ)
Abstract
Presentation thumbnail
Atorvastatin for prevention of chemotherapy-induced cardiotoxicity: a 5-year propensity-matched cohort study of 800 patients
Doctor R. Rascon Sabido (Veracruz, MX)
Abstract

Access the full session

Session thumbnail
Implementing novel lipid‑lowering therapies

The Event

Event poster

ESC Congress 2026

31 August 2026 09:15 CET
You may be interested in
thumbnail
Congress Presentation
Real-world use of rosuvastatin 40 mg and ezetimibe 10 mg after ACS: is this combination effective in achieving guideline-recommended LDL-C goals after discharge?
20 March 2026
thumbnail
Congress Session
For high-risk patients it's 15 minutes to midnight on the acute coronary syndrome (ACS) clock: can we stop it?
31 August 2024
thumbnail
Congress Presentation
Blood pressure and LDL-cholesterol control in patients with primary hypertension is far from optimal: results from a large observational, multicentric, prospective study
1 September 2019
thumbnail
Congress Presentation
Simulation study on LDL cholesterol target attainment, ASCVD events, and treatment cost of bempedoic acid in a representative German cohort of high- and very-high-CV risk patients
27 August 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources